<DOC>
	<DOCNO>NCT00003942</DOCNO>
	<brief_summary>RATIONALE : Inserting gene RevM10 person 's peripheral stem cell may improve body 's ability fight cancer make cancer sensitive chemotherapy . PURPOSE : Phase I/II trial study effectiveness RevM10-treated stem cell plus chemotherapy peripheral stem cell transplantation treat patient HIV-related non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Gene Therapy , Chemotherapy , Peripheral Stem Cell Transplantation Treating Patients With HIV-Related Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety infusion RevM10 RevM10/polAS transduce hematopoietic stem cell ( HSC ) addition high dose chemotherapy standard peripheral blood stem cell support patient HIV-1 relate non-Hodgkin 's lymphoma . II . Determine gene mark lymphocyte myeloid cell peripheral blood , bone marrow , and/or lymph node infusion RevM10-HSC RevM10/polAS-HSC patient . III . Determine antiretroviral effect treatment patient . OUTLINE : This multicenter study . Patients receive mobilization therapy undergo leukapheresis accord standard protocol . High dose chemotherapy administer day -7 -1 , also accord standard protocol . On day 0 , autologous hematopoietic stem cell transduce gene RevM10 RevM10/polAS infuse . Unmodified autologous peripheral blood stem cell reinfused day 1 . Patients follow daily 2 week , weekly 2 week , monthly 1 year , annually thereafter . PROJECTED ACCRUAL : Approximately 15 patient accrue study within 14 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : HIV1 infection document ELISA Western blot Histologically prove nonHodgkin 's lymphoma show least partial response standard chemotherapy regimen Poor prognosis first chemotherapy induced remission Increased LDH AND/OR Stage III IV AND/OR Reduced performance status ( ECOG 2 worse ) OR Response complete remission follow four course standard chemotherapy OR Responding relapse primary therapy No primary CNS lymphoma No uncontrolled meningeal lymphoma mobilization PATIENT CHARACTERISTICS : Age : 18 Performance status : See Disease Characteristics Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1500/mm3 Platelet count least 100,000/mm3 CD4 count least 100/mm3 Hepatic : Bilirubin le 2 mg/dL ( unless take indinavir ) SGOT SGPT less 2 time normal No hepatitis Renal : Creatinine le 2.0 mg/dL Pulmonary : DLCO great 60 % Other : Not pregnant nursing Fertile patient must use effective contraception No active Mycobacterium aviumintracellulare infection CMV disease No cerebral toxoplasmosis cryptococcal meningitis At least 6 month since prior alcohol substance abuse At least 1 year since CNS disease seizures No medical condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No concurrent chemotherapy Kaposi 's sarcoma Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : At least 30 day since prior treatment serious opportunistic infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2000</verification_date>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related diffuse large cell lymphoma</keyword>
	<keyword>AIDS-related immunoblastic large cell lymphoma</keyword>
	<keyword>AIDS-related small noncleaved cell lymphoma</keyword>
	<keyword>AIDS-related diffuse mixed cell lymphoma</keyword>
	<keyword>AIDS-related diffuse small cleave cell lymphoma</keyword>
	<keyword>AIDS-related lymphoblastic lymphoma</keyword>
</DOC>